Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept randomized withdrawal study in polyarticular juvenile rheumatoid arthritis
2005-000443-28Phase 3
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2011
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of abatacept in juvenile idiopathic arthritis (JIA) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Time to JRA/JIA disease flare during the double-blind treatment period.
02
Drugs
abatacept
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2005-000443-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000443-28.